IL-28B genetic variation, gender, age, jaundice, hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus.

Background/aims: Spontaneous viral clearance observed in some patients is one of the variants of the hepatitis C virus (HCV) infection natural history. We aimed to look at the complexity of factors affecting the spontaneous clearance of HCV (SC HCV).

Materials And Methods: A total of 357 anti-HCV positive patients (309 with chronic hepatitis C and 48 patients with SC HCV) were included into the study.

[Retherapy with lamivudine in hbeag-negative chronic hepatitis B patients unresponsive to interferon/peginterferon treatment].

The paper gives data on retherapy with lamivudine in seven HBeAg-negative chronic hepatitis B patients previously unresponsive to interferon-alpha and peginterferon-alpha2b therapy (6 unresponsive patients and 1 with recurrence). Prior to lamivudine therapy, hepatic biopsy and HBV genotyping were carried out and the baseline level of viremia and the presence of YMDD mutations were determined in all the patients. Its therapeutic efficiency was based on viremia level and AIAT activity at 6, 12, 18, and 24 weeks of treatment.

[Spontaneous HCV clearance: an association with gender, age, viral genotypes, infection transmission routes, and markers of HBV and HIV].

Aim: To determine the rate of spontaneous recovery depending on gender, age, prior icteric hepatitis, infection transmission routes, HCV genotype, markers of HBVand HIV.

Subjects And Methods: A humoral immunity response to core antigen and nonstructural viral proteins was assessed in patients with HCV clearance and in a group of patients with chronic hepatitis C (CHC). Two hundred and thirty-eight anti-HCV positive patients were examined.

[The use of recombinant alfa-2 interferon in treating patients with acute and chronic viral hepatitis B].

Efficiency was assessed of antiviral therapy with recombinant alfa-2 interferon in 90 patients with acute viral hepatitis B and 18 patients with chronic active hepatitis (ChAH). Intramuscular administration of interferon 1,000,000 to 3,000,000 units, during the first days of the illness over 10 to 14 days significantly reduced the duration of HBs-antigenemia and accelerated the regression of clinical and biochemical symptoms of the disease. These positive changes coincided with augmentation in the peripheral blood of T-suppressors and active T-cells.

[The course and outcome of viral hepatitis B in drug-addicted patients].

In this paper, characterization is given of clinical and biochemical features of VH B course against the background of narcomania. Recordable in such patient populations are high percentage of delta hepatitis (14.2%), unusual severity of the intoxication syndrome, protracted course with exacerbations (12.